Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria Triviño Ibáñez, Eva María Sánchez-Vañó, Raquel Sopena Novales, Pablo Romero Fábrega, Juan Carlos Rodríguez Fernández, Antonio Carnero Pardo, Cristóbal Martínez Lozano, María Dolores Gómez Río, Manuel Alzheimer’s disease Appropriate use criteria Amyloid PET Mild cognitive impairment Florbetaben PET To evaluate the use of amyloid-positron emission tomography (PET) in routine clinical practice, in a selected population with cognitive impairment that meets appropriate use criteria (AUC). A multicenter, observational, prospective case-series study of 211patients from 2 level-3 hospitals who fulfilled clinical AUC for amyloid-PET scan in a naturalistic setting. Certainty degree was evaluated using a 5-point Likert scale: 0 (very low probability); 1 (low probability); 2 (intermediate probability); 3 (high probability); and 4 (practically sure), before and after amyloid PET. The treatment plan was considered as cognition-specific or noncognition-specific. Amyloid-PET was positive in 118 patients (55.9%) and negative in 93 patients (44.1%). Diagnostic prescan confidence according amyloid-PET results showed that in both, negative and positive-PET subgroup, the most frequent category was intermediate probability (45.7% and 55.1%, respectively). After the amyloid-PET, the diagnostic confidence showed a very different distribution, that was, in the negative-PET group the most frequent categories are very unlikely (70.7%) and unlikely (29.3%), while in the positive- PET group were very probable (57.6%) and practically sure (39%). Only in 14/211 patients (6.6%) the result of the amyloid-PET did not influence the diagnostic confidence, while in 194 patients (93.4%), the diagnostic confidence improved significantly after amyloid- PET results. The therapeutic intention was modified in 93 patients (44.1%). Specific treatment for Alzheimer disease was started, before amyloid-PET, in 80 patients (37.9%). This naturalistic study provides evidence that the implementation of amyloid-PET is associated with a significant improvement in diagnostic confidence and has a high impact on the therapeutic management of patients with mild cognitive impairment fulfilled clinical AUC. 2020-05-14T11:28:59Z 2020-05-14T11:28:59Z 2019 info:eu-repo/semantics/article Triviño-Ibáñez, E. M., Sánchez-Vañó, R., Sopena-Novales, P., Romero-Fábrega, J. C., Rodríguez-Fernández, A., Pardo, C. C., ... & Gómez-Río, M. (2019). Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine, 98(29). http://hdl.handle.net/10481/62085 10.1097/MD.0000000000016509 eng http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Atribución-NoComercial-SinDerivadas 3.0 España Wolters Kluwer Health, Inc